Company News

Dermatology Drug Market To Grow 8% a Year to 2008

The Dermatology Drug market will grow 8% a year to 2008, led by demand for psoriasis treatments, according to the “Dermatology pipeline analysis: a market with room to grow” report by Decision Resources (DR), Waltham, MA. This is largely due to the Food and Drug Administration’s approval of Enbrel, an Amgen-based treatment for adults with moderate-to-severe chronic plaque psoriasis. Medications for atopic dermatitis will also increase, but uticario medications will decline.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters